NovoLog (insulin aspart)
NovoLog (insulin aspart) is rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus (1).
NovoLog (insulin aspart [rDNA origin] injection) is a rapid-acting human insulin analog used to lower blood glucose. NovoLog is homologous with regular human insulin with the exception of a single substitution of the amino acid proline by aspartic acid in position B28, and is produced by recombinant DNA technology utilizing Saccharomyces cerevisiae (baker’s yeast). Insulin aspart has the empirical formula C256H381N65079S6 and a molecular weight of 5825.8.
Mechanism of Action
The primary activity of NovoLog is the regulation of glucose metabolism. Insulins, including NovoLog, bind to the insulin receptors on muscle and fat cells and lower blood glucose by facilitating the cellular uptake of glucose and simultaneously inhibiting the output of glucose from the liver.
Studies in normal volunteers and patients with diabetes demonstrated that subcutaneous administration of NovoLog has a more rapid onset and a shorter duration of action than regular human insulin.
DOSAGE FORMS AND STRENGTHS
NOVOLOG 100 units per mL (U-100) is available as a clear and colorless
solution for injection in:
10 mL vials
3 mL PenFill cartridges for the 3 mL PenFill® cartridge delivery device with NovoFine disposable needles
3 mL NOVOLOG FlexPen and 3 mL NOVOLOG FlexTouch